Burkholderia cenocepacia zinc metalloproteases influence resistance to antimicrobial peptides.
Burkholderia cenocepacia secretes two zinc-dependent metalloproteases, designated ZmpA and ZmpB. Previously, ZmpA and ZmpB have been shown to cleave several proteins important in host defence. In this study, the ability of ZmpA and ZmpB to digest and inactivate antimicrobial peptides involved in innate immunity was examined. ZmpB but not ZmpA cleaved beta-defensin-1. ZmpA but not ZmpB cleaved the cathelicidin LL-37. Both enzymes cleaved elafin and secretory leukocyte inhibitor, which are antimicrobial peptides as well as neutrophil elastase inhibitors. Both ZmpA and ZmpB cleaved protamine, a fish antimicrobial peptide, and a zmpA zmpB mutant was more sensitive to protamine killing than the parental strain. ZmpA or ZmpB cleavage of elafin inactivated its anti-protease activity. The effect of ZmpA and ZmpB on the neutrophil proteases elastase and cathepsin G was also examined but neither enzyme was active against these host proteases. These studies suggest that ZmpA and ZmpB may influence the resistance of B. cenocepacia to host antimicrobial peptides as well as alter the host protease/anti-protease balance in chronic respiratory infections.
Kooi
Cora
C
Department of Microbiology and Infectious Diseases, University of Calgary, Calgary AB T2N 4N1, Canada.
Sokol
Pamela A
PA
Department of Microbiology and Infectious Diseases, University of Calgary, Calgary AB T2N 4N1, Canada.
D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D023181:Antimicrobial Cationic Peptides / Q000494:pharmacology* / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000378:metabolism*; D019121:Burkholderia Infections / Q000188:drug therapy / Q000378:metabolism; D016956:Burkholderia cepacia / Q000187:drug effects / Q000201:enzymology*; D024881:Drug Resistance, Bacterial; D053492:Elafin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008666:Metalloendopeptidases / Q000378:metabolism*; D008826:Microbial Sensitivity Tests; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000494:pharmacology / Q000627:therapeutic use; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D013379:Substrate Specificity; D023084:alpha-Defensins / Q000494:pharmacology / Q000627:therapeutic use; D023083:beta-Defensins / Q000494:pharmacology / Q000627:therapeutic use; D054804:Cathelicidins
D000890:Anti-Infective Agents; D023181:Antimicrobial Cationic Peptides; D001426:Bacterial Proteins; D053492:Elafin; D053481:Secretory Leukocyte Peptidase Inhibitor; D015842:Serine Proteinase Inhibitors; D023084:alpha-Defensins; D023083:beta-Defensins; C412019:ZmpB enzyme; D008666:Metalloendopeptidases; C502465:ZmpA protein, Burkholderia cenocepacia; D054804:Cathelicidins